In a report released today, Danielle Brill from Raymond James maintained a Hold rating on Zogenix (ZGNX). The company’s shares closed last Friday at $22.53.
According to TipRanks.com, Brill is a 4-star analyst with an average return of 18.4% and a 55.6% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zogenix with a $42.67 average price target.
See today’s analyst top recommended stocks >>
Zogenix’s market cap is currently $1.17B and has a P/E ratio of -6.00. The company has a Price to Book ratio of 4.03.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical company. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.
